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Background: Immuno-oncology (I-O) therapies target the host immune system, providing the potential to
choose a uniform dose and schedule across tumor types. However, dose selection for I-O agents usually
occurs early in clinical development and is typically based on tumor response, which may not fully represent
the potential for improved overall survival. Here, we describe an integrated approach which incorporates clinical safety
and efficacy data with data obtained from analyses of dose-/exposure-response (D-R/E-R) relationships, used to select
a monotherapy dose for nivolumab, a programmed death–1 inhibitor, in clinical studies of different tumor types.
Methods: Dose was selected based on anti-tumor activity and safety data from a large phase 1b, open-label,
dose-escalation study of nivolumab at doses ranging from 0.1 to 10 mg/kg administered every 2 weeks
(Q2W) in 306 patients with advanced malignancies, and quantitative analyses were performed to characterize
D-R/E-R relationships for pharmacodynamic, safety, and efficacy endpoints.
Results: A maximum tolerated dose for nivolumab was not identified, and the safety profile was similar across tumor
types and dose levels (0.1–10 mg/kg). Objective response rates (ORRs) were similar across doses in melanoma and
renal cell carcinoma (RCC), while higher ORRs were observed in non-small cell lung cancer (NSCLC) at 3 mg/kg and
10 mg/kg versus 1 mg/kg. Peripheral receptor occupancy was saturated at doses≥ 0.3 mg/kg. In D-R/E-R analyses, a
positive dose-dependent objective response trend was observed for each tumor type, but appeared to plateau at
nivolumab doses of≥ 1 mg/kg for melanoma and RCC, and at≥ 3 mg/kg for NSCLC. Although there was no apparent
relationship between tumor shrinkage rate and exposure, tumor progression rate appeared to decrease with increasing
exposure up to a dose of 3 mg/kg Q2W for NSCLC.
Conclusions: Nivolumab monotherapy at 3 mg/kg Q2W provides unified dosing across tumor types. This dose and
schedule has been validated in several phase II/III studies in which overall survival was an endpoint. Integrating D-R/E-R
relationships with efficacy data and a safety profile that is unique to I-O therapy is a rational approach for
dose selection of these agents.
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The oncology treatment landscape has changed consid-
erably in the past decade due to a deeper understanding
of tumor biology and tumor-immune interactions at a
molecular level. Although there have been clear ad-
vances, room remains for significant improvement with
regard to the success rate of pivotal clinical trials [1]. A
possible reason for this shortfall is that the dose selected
to be tested in pivotal trials has traditionally been based
on the maximum tolerated dose (MTD) paradigm. Al-
though often appropriate for cytotoxic drugs, the MTD
may not be the best approach for selecting phase III
doses of targeted and immuno-oncology (I-O) agents,
especially for well-tolerated agents, where MTD may not
even be determined [2]. Furthermore, the toxicity profile
of targeted and I-O agents differs from that of cytotoxic
therapy, and the typical 4-week observation period that
is used to identify dose-limiting toxicities (DLTs) may
not be sufficient. I-O treatments are associated with a
distinctive class of immune-related adverse events (AEs)
for which exposure-safety relationships are not yet well
understood. Moreover, in early-stage clinical trials when
exposure-response (E-R) relationships are typically ana-
lyzed, data are often limited by low numbers of patients
and limited exposure durations. Taken together, these
factors can contribute to selecting a suboptimal bio-
logical dose [3].
Dose selection for I-O treatments presents additional
unique challenges. Overall survival (OS) is considered the
standard endpoint for anti-cancer agents. However, OS is
associated with long follow-up times and other early clin-
ical efficacy endpoints (such as Response Evaluation Cri-
teria In Solid Tumors [RECIST] tumor response) may not
fully represent the potential clinical benefit in pivotal trials
[4]. In vivo models are often limited in predicting clinical
efficacy of a given dose and schedule of an I-O agent.
Taken together, these factors make phase III dose and
schedule selection challenging for I-O agents.
Conversely, I-O drugs may allow identifying a uniform
monotherapy dose and scheduling across tumor types
and stages of disease. This hypothesis is based on the
fact that their mechanisms of action promote anti-tumor
activity through direct effects on immune regulatory
pathways. Thus, while the characteristics of different
tumor types may vary widely, anti-tumor immune
response is a core mechanistic feature of I-O agents.
Several I-O agents have been approved, including ipili-
mumab, a cytotoxic T-lymphocyte antigen–4 (CTLA-4)
immune checkpoint inhibitor, as well as the pro-
grammed death–1 (PD-1) immune checkpoint inhibitors
nivolumab and pembrolizumab and the PD-1 ligand
(PD-L1) inhibitor atezolizumab. However, one of the
earliest, if not the first, published investigations of E-R
relationships for an I-O agent was performed withipilimumab [5, 6]. In those analyses, which were based
on population pharmacokinetics (PPK) modeling, higher
steady-state trough concentrations (Cminss) were associ-
ated with improved OS and increased anti-tumor activity
but with a higher incidence of immune-related AEs.
Ultimately, ipilimumab monotherapy demonstrated
superior OS in a phase III trial in patients with previ-
ously treated metastatic melanoma at a dose level and
schedule of 3 mg/kg every 3 weeks (Q3W) for up to four
doses [7]. These results indicate that characterizing the
relationships between pharmacokinetics (PK) (ie, expos-
ure) and key clinical outcomes from phase I and II trials
represents a valid approach to dose selection for I-O
agents.
Here, we describe the multifactorial considerations
employed in selecting a monotherapy dosing regimen
that was investigated in phase III trials of nivolumab
across three tumor types (melanoma, non-small cell lung
cancer [NSCLC], and renal cell cancer [RCC]). The
phase III dosing regimen was selected based on an
integrated analysis of safety and efficacy across tumor
type and dose level, and dose-response (D-R)/E-R re-
lationships of efficacy, safety, and pharmacodynamic
biomarkers from a large phase Ib study in patients
with advanced or recurrent solid malignancies [8].
The nivolumab dosing regimen selected was shown to
be safe and effective in four large, randomized, con-
trolled trials [9–12].
Methods
Patients and study design
Patients included in the nivolumab dose selection
analysis (N = 306) had participated in a large phase Ib
open-label, dose-escalation, cohort-expansion study to
evaluate the anti-tumor activity and safety of nivolumab in
previously treated advanced or recurrent malignancies
across advanced melanoma, NSCLC (including both squa-
mous and non-squamous), RCC, metastatic castration-
resistant prostate cancer (mCRPC), or colorectal cancer
(CRC) (CA209-003; Additional file 1: Figure S1) [8].
Patients received nivolumab at doses ranging from 0.1 to
10 mg/kg every 2 weeks (Q2W) administered as an intra-
venous infusion, for up to 2 years, unless they had a
complete response (CR), unacceptable AEs, progressive
disease (PD), or withdrew consent. Tumor response as-
sessments were conducted every 8 weeks. All participants,
or their legal representatives, gave written informed con-
sent prior to enrollment.
Patients across tumor types were enrolled into cohorts
of 3–6 per dose level. Dose escalation proceeded when a
minimum of three patients had completed the safety
evaluation period (56 days) at a given dose level, with
DLTs observed in less than one third of patients. Intra-
patient dose escalation was not permitted.
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anoma (assigned to a dose of 0.1, 0.3, 1, 3, or 10 mg/kg),
NSCLC (either squamous or non-squamous, assigned to
a dose of 1, 3, or 10 mg/kg), and RCC (at a dose of 1 or
10 mg/kg).
Safety
Safety evaluations were conducted for all treated patients
at baseline and at regular intervals. The severity of AEs
was graded according to the National Cancer Institute
Common Terminology Criteria for Adverse Events, v3.0
[13]. AEs were coded with the use of the Medical Dic-
tionary for Regulatory Activities (MedDRA), version
15.1. Select AEs, defined as those with a potential im-
munologic cause, were coded with the use of a prede-
fined list of MedDRA terms.
Efficacy
The efficacy population consisted of patients in whom
the response could be evaluated and who had measur-
able disease at baseline with one of the following: at least
one scan obtained during treatment, clinical evidence of
disease progression, or death.
Efficacy endpoints included objective response rate
(ORR) and progression-free survival at 24 weeks (PFSR
24). ORR was based on best overall response (BOR) of
CR and partial response (PR) as derived by the sponsor
using RECIST v1.1 criteria [14]. Objective responses
were confirmed by at least one sequential tumor assess-
ment, scheduled at screening and between days 52 and
56 of each cycle, and ORR was calculated as (CR + PR)/
number of patients × 100 in the study population. The
confidence intervals for ORR were based on the Clopper
Pearson interval.
PFSR 24 was calculated as the proportion of patients
without disease progression or death at 24 weeks, ac-
cording to the Kaplan-Meier method, with confidence
intervals using the Greenwood method.
Integrated PK, D-R/E-R analyses
Nivolumab PK
Nivolumab PK was characterized by an integrated PPK
approach with intensive and sparse PK data from 343
patients with solid tumors, who were enrolled in a pilot
phase I study (N = 39) and large phase Ib (N = 304) study
[8, 15]. The effects of the following covariate-parameter
relationships were estimated in the PPK model: baseline
body weight, age, sex, estimated glomerular filtration
rate (GFR), lactate dehydrogenase (LDH), albumin,
total bilirubin, C-reactive protein, and absolute
lymphocyte count on clearance and body weight and
sex on central volume of distribution. Visual predict-
ive check was used to evaluate the performance of
the PPK model, and summary measures of steady-state trough, peak, and time-averaged concentration
(Cminss, Cmaxss, and Cavgss) were determined for
each patient for whom nivolumab concentration data
were available [16].
Pharmacodynamics
To determine D-R of the pharmacodynamic biomarker,
receptor occupancy (RO), serum concentrations of nivo-
lumab were quantified with the use of an enzyme-linked
immunosorbent assay. In the phase Ib study, peripheral-
blood mononuclear cells were isolated from patients at
baseline and after the first treatment cycle to estimate
RO of PD-1 by nivolumab on circulating CD3+ T cells
by means of flow cytometry at baseline and week 8 post-
treatment [8, 15]. The available RO data were fitted to a
maximum possible effect (Emax) model as a function of
nivolumab concentration [15].
D-R analyses for safety and tolerability
D-R relationships of safety and tolerability were exam-
ined with respect to grade ≥ 3 AEs, AEs leading to dis-
continuation, as well as maintenance of dose-intensity.
The D-R of time-to-event of grade ≥ 3 AEs and AEs
leading to discontinuation were described by Kaplan-
Meier analyses of pooled safety data across tumor types
of patients enrolled in the phase Ib study. Dose interrup-
tion was allowed in the phase Ib study, and tolerability
was also examined graphically by plotting dose intensity
versus time.
E-R analyses for efficacy
Nivolumab E-R relationships of efficacy were investi-
gated with respect to confirmed objective response, and
tumor growth dynamics (TGD). Assessment of the rela-
tionship of nivolumab Cminss and TGD model esti-
mated shrinkage and progression rates complements the
more conventional assessment of efficacy by OR, by
enabling an assessment of the nivolumab on the entire
longitudinal time-profile of tumor response that goes
beyond the effect on categories of BOR.
The E-R of OR was described by separate logistic re-
gression models for each of the following tumor types:
melanoma, NSCLC, and RCC. Linear, log-linear, and
non-parametric (restricted cubic spline) functional forms
of Cminss were assessed in the logit function. Potentially
modulatory covariate effects were not included in E-R
models, given the limited data available at the time of
dose selection.
The logistic regression analysis of E-R of OR found
that the probability of OR was best described by log-
transformed steady-state trough concentration (Cminss),
in each of the tumor types (melanoma, NSCLC, and
RCC), which suggests that the probability of OR in-
creases with increasing Cminss for each of these tumor
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sponders was highest with 3 mg/kg in each of these
tumor types. Exploratory analysis of OR revealed that
the subset of patients with higher Cminss within a dose
tended to respond better than some patients at higher
doses who had even higher Cminss. Thus, further ex-
ploratory analysis was performed to investigate the rea-
son for the inconsistency between the observed and
model predicted responses.
The time course of tumor size was characterized by a
non-linear mixed-effect TGD model described previ-
ously [17]. Specifically, the tumor size (sum of longest
diameter of index lesions) at each tumor assessment visit
was described by the following equation:
TSi tð Þ ¼ BTS ið Þ  e−SRit þ PRi  t;
where TSi(t) is the tumor size at time t for the ith
patient; and BTSi, SRi, and PRi represent baseline tumor
size, tumor shrinkage rate constant, and linear tumor
progression rate for the ith patient, respectively.
The relationship between nivolumab Cminss and TGD
model parameters (SR and PR) were evaluated by tumor
type.
Results
A total of 306 patients with advanced solid tumors, in-
cluding melanoma (n = 107), NSCLC (n = 129 [including
74 with non-squamous, 54 with squamous, and 1 with
unknown histology]), RCC (n = 34), CRC (n = 19), and
mCRPC (n = 17) received treatment with nivolumab
monotherapy in the phase Ib study between October1.0
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Fig. 1 Exposure-response efficacy analysis of nivolumab by tumor type. Ve
CI = confidence interval; Cminss = steady-state nivolumab trough concen
Obs Prob = observed probability; OR = objective response; Pred Prob = p2008 and March 2013 (see Additional file 2: Table S1).
Baseline characteristics have been described previously
[8]. Safety data are presented for all patients who re-
ceived at least one dose of nivolumab. Efficacy data are
presented for 270 patients with melanoma, NSCLC, and
RCC. The protocol specified dosing frequency was Q2W
for all patients in the study.
No MTD was identified up to the highest dose tested
(10 mg/kg Q2W). Overall, nivolumab was considered
safe and tolerable up to 10 mg/kg Q2W. The median
duration of therapy across all tumor types and doses was
16.1 weeks (Additional file 3: Table S2 and Additional
file 4: Figure S2). A relative dose intensity of ≥ 90 % was
achieved in 265 (86.6 %) treated patients. Based on dose
intensity, patients received 10 mg/kg Q2W without con-
tinued discontinuations.
Overall, the safety profile of nivolumab monotherapy
was generally manageable and was consistent with the
mechanism of action of nivolumab. No MTD was
reached at doses tested up to 10 mg/kg Q2W. The na-
ture, frequency, and severity of treatment-related AEs
were similar across dose levels (Table 1) and tumor types
(Table 1 and Fig. 2), as were AEs leading to discontinu-
ation. The most common reason for discontinuation was
disease progression (n = 193, 67.5 %). Of all treated
patients, 43 (14.1 %) delayed study drug and 11 (3.8 %)
discontinued permanently due to an AE. Deaths were re-
ported in 75 patients (24.5 %) within 100 days of the last
dose of nivolumab. While most deaths (70 of 75; 93 %)
were due to malignant disease, a total of five deaths were
due to treatment-related pneumonitis (four with NSCLC




Obs Prob: 1 mg/kg
Obs Prob: 3 mg/kg
Obs Prob: 10 mg/kg
rtical lines represent 90 % prediction intervals for each dose level.
tration; MEL = melanoma; NSCLC = non-small cell lung cancer;
redicted probability; RCC = renal cell carcinoma
Table 1 Safety profile of nivolumab by dose level and tumor type
Dose (mg/kg Q2W)
Patients with treatment-related AEs, % (n) 0.1 0.3 1 3 10 Total
(N = 17) (N = 18) (N = 86) (N = 54) (N = 131) (N = 306)
Any grade 77 (13) 78 (14) 81 (70) 74 (40) 71 (93) 75 (230)
Grade 3/4 29 (5) 17 (3) 14 (12) 20 (11) 16 (21) 17 (52)
Serious grade 3/4 6 (1) 0 5 (4) 9 (5) 11 (14) 8 (24)
Leading to DC 18 (3) 0 11 (9) 7 (4) 12 (16) 11 (32)
Deaths – – 2 (2) 4 (2) 1 (1) 2 (5)
Tumor type
Patients with treatment-related AEs, % (n) NSCLC MEL RCC CRC mCRPC Total
(N = 129) (N = 107) (N = 34) (N = 19) (N = 17) (N = 306)
Dose levels (mg/kg) 1–10 0.1–10 1, 10 10 10
Any grade 71 (91) 84 (90) 85 (29) 58 (11) 53 (9) 75 (230)
Grade 3/4 14 (18) 22 (24) 18 (6) 16 (3) 6 (1) 17 (52)
Serious grade 3/4 6 (8) 9 (10) 9 (3) 11 (2) 6 (1) 8 (24)
Leading to DC 12 (16) 9 (10) 9 (3) 16 (3) 0 11 (32)
Deaths 3 (4) – – 5 (1) – 2 (5)
AE adverse event, CRC colorectal cancer, DC discontinuation, mCRPC metastatic castration-resistant prostate cancer, MEL melanoma, NSCLC non-small cell lung
cancer, Q2W every 2 weeks
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Generally, AEs were manageable and reversible with the
use of immuno-suppressants.
There was no apparent relationship between the inci-
dence of select AEs and the dose of nivolumab. Inte-
grated D-R for safety was assessed with respect to the
cumulative time-to-event distribution of grade ≥ 3
treatment-related AEs and AEs leading to discontinu-
ation across all tumor types in the dose-ranging phase Ib
study (Fig. 2). The probability of AEs leading to discon-
tinuation appeared to be lower in doses ≤ 1 mg/kg com-
pared with the 3 and 10 mg/kg doses. The probabilities
of both grade ≥ 3 treatment-related AEs and those lead-
ing to discontinuation were similar between 3 and
10 mg/kg doses. In addition, relative dose intensity
across dose levels appeared to be > 90 % for all dose
levels. The average dose intensity per patient was 1.0,
2.9, and 9.8 mg/kg/2 weeks for 1.0, 3.0, and 10.0 mg/kg
dose levels, respectively.
Overall, with no established MTD, similar dose inten-
sity, nature, and frequency of AEs across dose levels, and
manageable safety profile of nivolumab, 10 mg/kg Q2W
was considered safe and tolerable.
In the 69 evaluated patients with melanoma, periph-
eral PD-1 RO was saturated at ≥ 0.3 mg/kg doses after
8 weeks (Fig. 3a). The E-R relationship for RO is shown
in Fig. 3b. Peripheral RO is saturated at a lower concen-
tration with doses corresponding to ≥ 0.3 mg/kg. In
addition, there were minor increases in activated T cells
in peripheral blood, with no evidence of D-R. Theperipheral pharmacodynamics data did not differentiate
activity by dose level. However, it should be noted that
the relationship between peripheral and intra-tumoral
PD-1 RO and T-cell proliferation has not been estab-
lished and may have limited value in understanding D-R
relationships.
ORRs were similar across the evaluated dose ranges
for melanoma and RCC. However, higher ORRs were
observed for NSCLC at 3 (24.3 %) and 10 mg/kg
(20.3 %) than at 1 mg/kg Q2W (3 %) (Table 2). The
PFSR 24 was numerically higher at 3 mg/kg for melan-
oma and NSCLC than at other doses tested (melanoma:
0.1, 0.3, 1, and 10 mg/kg; NSCLC: 1 and 10 mg/kg). For
RCC, ORRs were similar for 1 and 10 mg/kg, and PFSR
24 was numerically higher at 10 mg/kg than at 1 mg/kg
(Table 2).
The E-R for efficacy was evaluated for multiple end-
points, such as objective response (OR), representing
early clinical activity and TGD modeling, which is inde-
pendent of follow-up and not affected by unconventional
responses seen with cancer immunotherapy. In order to
characterize the E-R for efficacy with OR, a log-linear
function of Cminss was selected for logistic regression
for three tumor types. As shown in Fig. 1, a trend was
observed between the probability of OR and higher
Cminss, but this appeared to plateau at doses ≥ 1 mg/kg
for melanoma and ≥ 3 mg/kg for NSCLC. The E-R rela-
tionship for RCC appeared linear, although it should be
noted that only two doses (1 and 10 mg/kg) were evalu-
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Fig. 2 Integrated dose-response for treatment-related grade ≥3 AEs and AEs leading to discontinuation. AEs = adverse events
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from 69 MEL pts
Fig. 3 Peripheral a PD-1 occupancy and b receptor occupancy (RO) of patients treated with nivolumab. MEL =melanoma; PD-1 = programmed
death–1; pts = patients
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two doses.
Exploratory analyses revealed that the responders at
each dose level tended to be clustered at the higher ex-
posures compared with non-responders at the same doseTable 2 ORR and PFSR 24 rates by dose in patients with melanoma
MEL (N = 107) NSCLC
Dose (mg/kg) ORR % (n/N) PFSR 24, % ORR %
0.1 35 (6/17) 41 —
0.3 28 (5/18) 35 —
1 31 (11/35) 51 3 (1/33
3 41 (7/17) 55 24 (9/3
10 20 (4/20) 35 20 (12/
— = not tested, MEL melanoma, NSCLC non-small cell lung cancer, ORR objective re
cell carcinomalevel. Additionally, some of the patients tended to re-
spond better than others at higher dose levels who had
higher exposures. This phenomenon was further evalu-
ated by performing E-R analysis by dose (Fig. 4 for mel-
anoma and Additional file 5: Figure S3 and Additional, NSCLC, and RCC treated with nivolumab monotherapy
(N = 129) RCC (N = 34)
(n/N) PFSR 24, % ORR % (n/N) PFSR 24, %
— — —
— — —
) 26 28 (5/18) 50
7) 40 — —
59) 33 31 (5/16) 67
sponse rate, PFSR 24 progression-free survival rate at 24 weeks, RCC renal














































Fig. 4 Exposure-response for efficacy by dose level in melanoma.
a Probability of OR vs Cminss, overall and by dose. b Probability of
OR vs CL, overall and by dose. CL = clearance; Cminss = steady-state
trough concentration; OR = objective response
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dose-level E-R did not appear to be consistent with the
overall E-R. This result appeared more evident in the E-
R for melanoma, where the by-dose E-R curves for 1, 3,
and 10 mg/kg are approximately parallel. This pattern of
E-R suggested that nivolumab clearance may be associ-
ated with the probability of OR, such that patients with
inherently lower clearance tend to respond better. Clear-
ance was a highly significant predictor of response, and
the relationship between clearance and probability of
OR was consistent across patients at all dose levels
(Fig. 4). Although the results of TGD modeling were
different for each tumor type, there were no apparent
relationships between tumor shrinkage rates and expos-
ure. Tumor progression rate decreased with increasing
exposure for melanoma, NSCLC, and RCC; however,
higher exposures appear to be required for NSCLC to
achieve the maximum decrease in tumor progressionrate. The dose of ≥ 3 mg/kg Q2W provided the max-
imum decrease in tumor progression rate across all
tumor types (Fig. 5).
Overall these results showed that nivolumab is well
tolerated up to 10 mg/kg Q2W. Moreover, D-R/E-R
relationships for efficacy suggested that nivolumab at
1 mg/kg Q2W may be active for high-immunogenic
tumor types of melanoma and RCC. However, a dose
of 3 mg/kg Q2W may be required for the less-
immunogenic tumor type of NSCLC. Based on these
findings, the dose of nivolumab at 3 mg/kg Q2W was
selected as a monotherapy dose across tumor types.
Discussion
By targeting the patient’s immune system, I-O therapies
such as nivolumab provide the potential to identify a
uniform dose and schedule across multiple tumor types.
In this study, we integrated clinical efficacy, safety, RO,
and D-R/E-R modeling from a large phase Ib trial to
select a nivolumab monotherapy dose for further evalu-
ation. The totality of the clinical, pharmacodynamic
(RO), and D-R/E-R evidence indicated that a nivolumab
dosing regimen of 3 mg/kg Q2W would be likely to
maximize efficacy without risking the emergence of
safety and tolerability signals. Therefore, this dosing
regimen was selected for evaluation in subsequent
phase III trials.
Peripheral pharmacodynamic markers such as PD-1
RO did not provide meaningful demarcation for dose se-
lection; because peripheral RO was saturated at relatively
low exposures that corresponded to a nivolumab dose of
to 0.3 mg/kg Q2W. The utility of peripheral RO data is
also hampered by our limited understanding of the rela-
tionships between peripheral RO and intra-tumoral RO
and immune-modulating activity in the tumor microenvir-
onment. Interestingly, nivolumab treatment resulted in
minor increases in activated T cells in peripheral blood
with no evidence of D-R (data not shown). The peripheral
pharmacodynamic markers have shown limited D-R rela-
tionship and may not be used to select a dose for cancer
immunotherapy agents. Newer holistic approaches, such
as systems pharmacology modeling, may provide a better
understanding of the association between peripheral
markers and efficacy that could be used in drug develop-
ment plans.
Results from the investigation of exposure-efficacy re-
lationships for various efficacy endpoints indicate that
tumor types such as melanoma and RCC reached plat-
eaus in derived efficacy at lower exposures compared
with NSCLC. These relationships were seen for other
measures of efficacy, such as response rate, which repre-
sents an early clinical endpoint, and TGD, which is less
impacted by duration of follow-up or unconventional
































































Fig. 5 Relationship between a exposure and tumor shrinkage rate, and b exposure and tumor progression rate. Cminss = steady-state trough
concentration; MEL =melanoma; NSCLC = non-small cell lung cancer; RCC = renal cell carcinoma
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appeared to have higher nivolumab exposures than non-
responders at the same dose level. To further investigate
this observation, E-R analysis was performed at each
dose level. The predicted probability lines for each dose
level (1 vs 3 vs 10 mg/kg) were in parallel; thus, the E-R
of nivolumab may be confounded by nivolumabclearance. Interestingly, after a visual observation of
higher concentration for responders within a dose level,
an E-R was also observed within each dose even if the
exposure for non-responders was higher compared with
exposure of non-responders at lower dose levels. This
indicates that nivolumab baseline clearance, in addition
to exposure, may be a predictor for efficacy.
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complete and partial responders compared with patients
with stable or progressive disease. This relationship be-
tween nivolumab baseline clearance and efficacy appears
to be independent of the established relationship between
clearance and nivolumab exposure. Notably, clearance
was higher in patients with low baseline serum albumin,
which has been reported to be a risk factor for poor prog-
nosis in patients with cancer [18]. In addition, for mono-
clonal antibodies for cancer therapy, drug clearance may
be a surrogate for tumor-related factors such as tumor
burden and disease status that are not fully accounted for
by patient-specific covariates such as LDH or Eastern
Cooperative Oncology Group (ECOG) status [19]. In
order to differentiate the potential interplay between nivo-
lumab exposure and clearance on efficacy, ongoing studies
are refining the nivolumab E-R analyses with larger
phase III datasets by including clearance as a covariate in
the E-R modeling. However, it is important that contribu-
tion of effect of clearance and true E-R should be teased
out during dose selection for monoclonal antibodies in
cancer drug development. It is also recommended to
evaluate a minimum of two dose levels to study the con-
founding effect of clearance in dose-selection activity.
It should be noted that these analyses were performed
irrespective of PD-L1 expression due to the limited
availability of these data early in the nivolumab develop-
ment program. Therefore, the selected dose is likely to
provide optimal efficacy in a mixed PD-L1 expression
population. Subsequent phase III trials demonstrated
that the dose chosen from the integrated evaluation of
multiple endpoints across high- and low-immunogenic
tumor types resulted in survival benefits to patients irre-
spective of PD-L1 expression levels [4, 13, 20, 21]. In
NSCLC, 1-, 2-, and 3-year OS rates at 3 mg/kg were 56,
42, and 27 %, respectively [20]. Similarly, 1- 2-, 3-, and
4-year OS rates in melanoma at 3 mg/kg were 65, 47,
41, and 35 %, respectively [4]. Further validation of the
dose-selection methodology has subsequently been dem-
onstrated by the results of randomized phase III trials in
melanoma, NSCLC, and RCC, each meeting their re-
spective primary survival endpoints at the selected dose
and schedule [9–12].
Based on the above analyses, 3 mg/kg Q2W offers a
unified dose that provides optimized efficacy across mel-
anoma, RCC, and NSCLC tumor types. However, add-
itional studies are required to further optimize the
dosing regimen and treatment duration of immunother-
apeutic agents.
Although survival is the gold standard endpoint for
fully establishing efficacy for anti-cancer agents, early
tumor shrinkage could offer an appealing surrogate of
survival in the context of dose selection. This approach
was evaluated for cancer immunotherapy by correlatingipilimumab exposure, tumor shrinkage, and survival
[22]. Taken together, dose selection based on early effi-
cacy endpoints and TGD modeling can provide reason-
able confidence that a selected dose will result in
meaningful survival benefit.
Conclusions
In summary, an integrated methodology utilizing phase Ib
clinical activity, safety, D-R/E-R, and pharmacodynamic
data indicated an optimal biologic nivolumab monother-
apy dose of 3 mg/kg Q2W for further development across
different tumor types, and this dose was confirmed in sub-
sequent phase III trials that demonstrated the OS benefits
of nivolumab in patients with melanoma, NSCLC, and
RCC. The approaches and methodologies described may
be applied to emerging I-O agents where limited survival
data are available during the early stages of clinical
development.
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